JTCVS open最新文献

{"title":"Midterm outcomes of thoracic endovascular aortic repair versus optimal medical therapy for uncomplicated acute type B dissection","authors":"Kevin G. Hu BS ,&nbsp;Wei-Guo Ma MD ,&nbsp;Stevan Pupovac MD ,&nbsp;Irbaz Hameed MD ,&nbsp;Soraya Fereydooni MD ,&nbsp;Eric S. Li MD ,&nbsp;Haleigh Larson MD ,&nbsp;Mohammad Zafar MBBS ,&nbsp;Britt Tonnessen MD ,&nbsp;Jonathan Cardella MD ,&nbsp;Eduard Aboian MD ,&nbsp;Raul Guzman MD ,&nbsp;Cassius Ochoa Chaar MD ,&nbsp;David Strosberg MD ,&nbsp;Matthew Williams MD ,&nbsp;Naiem Nassiri MD ,&nbsp;Roland Assi MD ,&nbsp;Prashanth Vallabhajosyula MD, MS","doi":"10.1016/j.xjon.2024.12.013","DOIUrl":"10.1016/j.xjon.2024.12.013","url":null,"abstract":"<div><h3>Objective</h3><div>We sought to compare the early and midterm outcomes of thoracic endovascular aortic repair (TEVAR) versus optimal medical therapy (OMT) for uncomplicated acute type B aortic dissection.</div></div><div><h3>Methods</h3><div>Data were analyzed for 200 consecutive patients with uncomplicated acute type B aortic dissection from February 1992 to July 2022, including 147 with initial OMT and 53 undergoing TEVAR at index hospitalization. Baseline, intraoperative, and postoperative data, survival, and (re)intervention were compared between the two strategies.</div></div><div><h3>Results</h3><div>In-hospital/30-day mortality was 7.5% (15/200) for the entire series, which was significantly lower in the TEVAR group compared with the OMT group (0 vs 10.2% [15/147]; <em>P</em> = .013). Thirty-day rates were 5.7% (3/53) for reintervention after TEVAR and 15.6% (23/147) for intervention after OMT (<em>P</em> = .064). Death within 30 days of (re)intervention was 0 (n = 0) in the TEVAR group and 18.4% (n = 14) in the OMT group (<em>P</em> = .063). There were no significant differences in the incidences of stroke, paraplegia, acute kidney injury, sepsis, or malperfusion syndrome after initial treatment. Kaplan–Meier survival in the TEVAR group was 92.3% (95% CI, 80.7-97.0) at 1 year and 3 years, significantly higher than in the OMT group (80.3% [95% CI, 72.8-85.8] and 71.4% [95% CI, 63.4-78.0]; <em>P</em> = .012). In patients aged 65 years or more, TEVAR also achieved a significantly higher survival, which was 93.7% (95% CI, 77.5-98.3 vs 69.7% [95% CI, 58.0-78.7]) at 1 year and 93.7% (95% CI, 77.3-98.3] vs 60.5% [95% CI, 48.7-70.5]) at 3 years (<em>P</em> &lt; .001).</div></div><div><h3>Conclusions</h3><div>In this single-institution experience, upfront TEVAR performed at index hospitalization for uncomplicated acute type B aortic dissection was associated with improved survival at early and midterm follow-up.</div></div>","PeriodicalId":74032,"journal":{"name":"JTCVS open","volume":"24 ","pages":"Pages 67-76"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143854675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Delays in phases of care from identification to treatment of suspicious lung nodules","authors":"Nihar Rama BS ,&nbsp;Rachel Nordgren PhD ,&nbsp;Aliya N. Husain MD ,&nbsp;Aditya Juloori MD ,&nbsp;Christine M. Bestvina MD ,&nbsp;Rajat Thawani MD ,&nbsp;Marina Garassino MD ,&nbsp;Septimiu Murgu MD ,&nbsp;Ajay Wagh MD, MS ,&nbsp;D. Kyle Hogarth MD ,&nbsp;Carrie Barth MS ,&nbsp;Darren Bryan MD ,&nbsp;Mark K. Ferguson MD ,&nbsp;Jessica Donington MD ,&nbsp;Maria Lucia Madariaga MD","doi":"10.1016/j.xjon.2025.01.006","DOIUrl":"10.1016/j.xjon.2025.01.006","url":null,"abstract":"<div><h3>Objectives</h3><div>Shorter time to lung cancer diagnosis and treatment is associated with improved outcomes. We analyzed the time spent from nodule identification to treatment to identify targets for improving the timeliness of suspicious lung nodule care in a diverse patient population.</div></div><div><h3>Methods</h3><div>This was a retrospective cohort study of patients with suspicious lung nodules (suspected clinical stage I/II primary lung cancer) at a single academic medical center (2020-2022). Patients with suspected stage III/IV or nonprimary lung cancers were excluded. Multivariable Cox regressions were performed to assess factors associated with timeliness of care.</div></div><div><h3>Results</h3><div>Of 157 patients, 59% were female, 53% were Black, and mean age was 70 ± 8.6 years. Nodules were identified incidentally (52%) or via screening (48%). Treatment was surgery in 52% and stereotactic body radiotherapy in 44%, and 10.2% were benign. Median (interquartile range) times from referral to diagnosis and from referral to treatment were 34 (22-56) days and 65 (44-84) days, respectively. Consultation to biopsy (20 [12-34] days) and diagnosis to treatment (28 [8-43] days) were the longest phases of care. Longer time from referral to diagnosis was associated with Black race and widowed status, whereas longer time from referral to treatment was associated with female gender, widowed status, frailty, body mass index greater than 18.5, Eastern Cooperative Oncology Group performance status less than 2, bronchoscopic biopsy, and treatment with stereotactic body radiotherapy.</div></div><div><h3>Conclusions</h3><div>Increased time spent in suspicious lung nodule care is associated with demographic, social, and clinical factors. The longest phases are time from consultation to biopsy and from diagnosis to treatment. Improving multidisciplinary care coordination for vulnerable patient populations could improve the timeliness of suspicious lung nodule care.</div></div>","PeriodicalId":74032,"journal":{"name":"JTCVS open","volume":"24 ","pages":"Pages 451-471"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143854868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Young lung cancer patients undergoing surgery: Comparison of clinicopathological characteristics and outcomes in patients aged ≤50 years versus >50 years","authors":"Rachel T. Leo BA,&nbsp;Evert A. Sugarbaker BS,&nbsp;Miles McAllister BA,&nbsp;Anupama Singh MD,&nbsp;Rafael R. Barcelos MD,&nbsp;Ali Basil Ali MD,&nbsp;Raphael Bueno MD,&nbsp;Michael T. Jaklitsch MD,&nbsp;Paula Ugalde Figueroa MD,&nbsp;Scott J. Swanson MD","doi":"10.1016/j.xjon.2024.12.008","DOIUrl":"10.1016/j.xjon.2024.12.008","url":null,"abstract":"<div><h3>Objective</h3><div>We investigated clinicopathologic characteristics, overall survival (OS), and locoregional recurrence-free survival of young surgical patients with non–small cell lung cancer.</div></div><div><h3>Methods</h3><div>Retrospective review of an institutional database of patients aged 50 years or younger undergoing resection for non–small cell lung cancer between January 1995 and March 2022. A control group of patients older than age 50 years was selected by stratified random sampling. Relevant characteristics were compared with Wilcoxon rank sum,χ,² and Fisher exact tests. Propensity-score weighting was used to control for confounders. OS and locoregional recurrence-free survival were analyzed with Kaplan-Meier and Cox proportional hazards regression.</div></div><div><h3>Results</h3><div>We identified 196 patients aged 50 years or younger and 232 patients older than age 50 years. Median age was 46 years (interquartile range, 43-49 years) in the younger group and 69 years (interquartile range, 63-74 years) in the older group. Younger patients were more often women, non-White, and with fewer comorbidities. They more often presented with symptoms, stage III or IV disease, and more often received neoadjuvant therapy. In unweighted analysis, younger patients showed superior OS (log-rank <em>P</em> &lt; .0001). After propensity score weighting for procedure type, histologic type, Charlson Comorbidity Index, and smoking status, there was no significant difference in OS at 5 years between younger and older groups (70.62% vs 72.99%; weighted log-rank <em>P</em> = .084). Younger patients showed superior OS (weighted log-rank <em>P</em> = .0006) and locoregional recurrence-free survival (weighted log-rank <em>P</em> = .017) for clinical stage I, but not any other stage. lymphovascular invasion was an independent risk factor for worsened OS and locoregional recurrence-free survival across ages.</div></div><div><h3>Conclusions</h3><div>Recognizing lung cancer as a differential diagnosis for patients aged 50 years or younger is crucial because this group shows superior outcomes for stage I disease. Lymphovascular invasion is an independent prognostic risk factor across age groups.</div></div>","PeriodicalId":74032,"journal":{"name":"JTCVS open","volume":"24 ","pages":"Pages 409-422"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143854480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimal treatment for nonsevere coronary artery disease in valve surgeries: Concurrent coronary artery bypass grafting or postoperative medical therapy?","authors":"Li Ding MD, PhD","doi":"10.1016/j.xjon.2025.01.011","DOIUrl":"10.1016/j.xjon.2025.01.011","url":null,"abstract":"","PeriodicalId":74032,"journal":{"name":"JTCVS open","volume":"24 ","pages":"Pages 256-263"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143854579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Distal anastomosis new entry tear in acute type A aortic dissection: A risk factor for distal aortic reoperation","authors":"Rana-Armaghan Ahmad BS ,&nbsp;Prabhvir Marway MD ,&nbsp;Carlos Alberto Campello Jorge MD ,&nbsp;Katelyn Monaghan BS ,&nbsp;Divyaam Satija BS ,&nbsp;Carol Ling MS ,&nbsp;Shinichi Fukuhara MD ,&nbsp;Himanshu Patel MD ,&nbsp;G. Michael Deeb MD ,&nbsp;Nicholas Burris MD ,&nbsp;Bo Yang MD, PhD","doi":"10.1016/j.xjon.2025.02.016","DOIUrl":"10.1016/j.xjon.2025.02.016","url":null,"abstract":"<div><h3>Objective</h3><div>To identify predictive factors for the occurrence of a distal anastomosis new entry tear (DANE) in patients who underwent hemiarch replacement after acute type A aortic dissection (ATAAD) and examine the association of DANE with distal aortic reoperation.</div></div><div><h3>Methods</h3><div>Between 1996 and March 2021, 434 patients underwent hemiarch replacement for DeBakey I ATAAD, of whom 327 patients had adequate postoperative imaging. Based on the presence of DANE on postoperative computed tomography angiography, patients were divided into the DANE group (n = 81) and the no-DANE group (n = 246). Primary outcomes were the cumulative incidence of distal aortic reoperation and the risk factors for DANE.</div></div><div><h3>Results</h3><div>Most perioperative characteristics and outcomes, including age, sex, malperfusion syndromes, aortic diameters, and operative mortality were similar in the 2 groups. Using death as a competing factor, the 10-year cumulative incidence of distal aortic reoperation was higher in the DANE group compared to the no-DANE group (30% vs 12%; <em>P</em> = .0001). The hazard ratio for DANE in distal reoperations was 2.28 (<em>P</em> = .005). A multivariable regression model showed that having an aortic surgeon was protective against DANE compared to having a nonaortic surgeon (odds ratio [OR], 0.29; <em>P</em> = .05) and identified branch dissection (OR, 2.42; <em>P</em> = .002) as a risk factor for the occurrence of DANE. Connective tissue disease and large-bore suture (4-0 vs 5-0) were not associated with DANE.</div></div><div><h3>Conclusions</h3><div>Optimizing surgical techniques to prevent DANE in ATAAD repair may prevent the need for reoperation on the distal aorta in DeBakey type I ATAAD.</div></div>","PeriodicalId":74032,"journal":{"name":"JTCVS open","volume":"24 ","pages":"Pages 77-84"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143854676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preclinical experience with cisplatin, gemcitabine, and doxorubicin in pulmonary suffusion","authors":"Lindsay J. Nitsche BS ,&nbsp;Leslie Curtin DVM ,&nbsp;Sandra Sexton DVM ,&nbsp;Thaer Khoury MD ,&nbsp;Joshua D. Prey MS ,&nbsp;Sai Yendamuri MD ,&nbsp;Todd L. Demmy MD","doi":"10.1016/j.xjon.2024.12.012","DOIUrl":"10.1016/j.xjon.2024.12.012","url":null,"abstract":"<div><h3>Background</h3><div>Because suffusion amplifies lung chemotherapy while limiting systemic toxicity, we tested candidate drugs for treating human lung cancers and pulmonary metastases.</div></div><div><h3>Methods</h3><div>Immature beagle dogs underwent thoracotomy for unilateral lung suffusion of cisplatin (0.125-2 mg/kg; n = 19), doxorubicin (3.75-7.5 mg/kg; n = 7), gemcitabine (168.75 mg/kg; n = 5), or saline (n = 3). After ipsilateral lung circulation isolation and drainage, pulmonary artery chemotherapy was injected, dwelled for 30 minutes, and then aspirated. Bilateral lung biopsies and serum samples assessed delivery and leak. After lung reperfusion, animals recovered for 30 days with scheduled monitoring of vital signs, weights, and behaviors. At experiment termination, necropsy histopathologic tissue analyses assessed tolerability.</div></div><div><h3>Results</h3><div>All 32 animals recovered, except 1 with lung torsion and 2 with pulmonary toxicity that required early euthanasia. Serum concentrations during suffusion for cisplatin (135 ng/mL), doxorubicin (undetectable), and gemcitabine (1452 ng/mL) indicated minimal systemic leakage. Cisplatin escalations showed uniform suffusion deliveries (100% fibrosis at a 100% systemic chemotherapy dose), which was then reduced to a nondamaging 25% threshold. When the equivalent dose of doxorubicin was used, toxicity occurred, but 12.5% (2.5-fold amplification of local delivery) was well tolerated. Gemcitabine, like cisplatin, caused minimal toxicity at 25% of the systemic dose (5-fold amplification). Optimized doses caused no hematologic or metabolic derangements and necropsies showed no gross organ injury other than adhesions. Histopathology demonstrated multifocal ipsilateral lung fibrotic changes without contralateral or extrapulmonary pathology.</div></div><div><h3>Conclusions</h3><div>While suffusion delivery of the vesicant doxorubicin was tolerated less well than cisplatin and gemcitabine, all appear to be safe and feasible for human trials.</div></div>","PeriodicalId":74032,"journal":{"name":"JTCVS open","volume":"24 ","pages":"Pages 484-495"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143854869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research productivity among applicants who matched into an integrated thoracic surgery residency program: A bibliographic review","authors":"Nika Samadzadeh Tabrizi MD ,&nbsp;Michelle Shen BS ,&nbsp;Alexander D. Shapeton MD ,&nbsp;Isha Doshi MD ,&nbsp;Junyi Liu BS ,&nbsp;Thomas Fabian MD ,&nbsp;Patrick Chan MD","doi":"10.1016/j.xjon.2024.11.017","DOIUrl":"10.1016/j.xjon.2024.11.017","url":null,"abstract":"<div><h3>Background</h3><div>Research productivity is an important factor in candidate selection by integrated thoracic surgery residency programs, and thus tracking the research output of applicants who match into an integrated program is necessary. This study sought to examine the research productivity of matched integrated applicants prior to residency and to assess demographic, bibliographic, and institutional variables associated with continued research productivity during residency.</div></div><div><h3>Methods</h3><div>Bibliographic records of applicants who matched into an integrated thoracic surgery residency program from 2015 to 2022 were reviewed manually (eg, PubMed/MEDLINE, Scopus, Google Scholar, ResearchGate) to identify studies published up to January 2024. Publications were stratified by publication type and first authorship relative to the applicants’ match year. Individuals were analyzed by demographics, medical school ranking, and affiliated residency program research infrastructure.</div></div><div><h3>Results</h3><div>A total of 300 matched integrated applicants were identified. Among applicants who matched into an integrated program, the number of total (<em>P</em> = .001) and first-authorship (<em>P</em> = .006) publications prior to residency increased significantly from 2015 to 2022. Over the same period, the rates of total (<em>P</em> = .2) and first-authorship (<em>P</em> = .3) publications during residency remained relatively unchanged. Matched integrated applicants with a higher number of total and first-authorship publications prior to residency had higher rates of total publications (1.17; 95% confidence interval [CI], 1.09-1.25; <em>P</em> &lt; .001) and first-authorship publications (1.19; 95% CI, 1.13-1.26; <em>P</em> &lt; .001) publications during residency.</div></div><div><h3>Conclusions</h3><div>Research productivity among applicants who matched into an integrated thoracic surgery residency program from 2015 to 2022 has increased and is a strong predictor of sustained scholarly output during residency.</div></div>","PeriodicalId":74032,"journal":{"name":"JTCVS open","volume":"23 ","pages":"Pages 369-378"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143465078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply: Continental developments in African cardiothoracic surgery","authors":"Victory B. Effiom MD ,&nbsp;Anayo J. Michael MD ,&nbsp;Fatma K. Ahmed MD ,&nbsp;Achanga Bs. Anyinkeng MD ,&nbsp;Jonas L. Ibekwe MD ,&nbsp;Abdullah K. Alassiri MD ,&nbsp;Victor O. Femi-Lawal MD ,&nbsp;Eric E. Vinck MD","doi":"10.1016/j.xjon.2024.12.009","DOIUrl":"10.1016/j.xjon.2024.12.009","url":null,"abstract":"","PeriodicalId":74032,"journal":{"name":"JTCVS open","volume":"23 ","pages":"Page 387"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143465081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Routine use of jejunostomy tubes after esophagectomy: The good, the bad, and the ugly!","authors":"Sadia Tasnim MD, MS ,&nbsp;Siva Raja MD, PhD ,&nbsp;Sadhvika Ramji MD ,&nbsp;Rachel NeMoyer MD, MPH ,&nbsp;Eugene H. Blackstone MD ,&nbsp;Andrew J. Toth MS ,&nbsp;John O. Barron MD ,&nbsp;Daniel P. Raymond MD ,&nbsp;Sudish C. Murthy MD, PhD ,&nbsp;Monisha Sudarshan MD, MPH","doi":"10.1016/j.xjon.2024.09.032","DOIUrl":"10.1016/j.xjon.2024.09.032","url":null,"abstract":"<div><h3>Objective</h3><div>The study objective was to assess adverse events, readmissions, and resource use associated with routine jejunostomy tube placement after esophagectomy.</div></div><div><h3>Methods</h3><div>From September 2018 to October 2021, 215 patients, with a median age of 65 years and a median body mass index of 27 kg/m², underwent routine jejunostomy tube placement during esophagectomy. J-tube–related adverse events were collected from date of surgery to date of removal and categorized as (1) nonserious, resource-nonintensive (eg, skin irritations, discomfort); (2) nonserious, resource-intensive (eg, infection, clogged, and dislodged tubes); and (3) serious, resource-intensive (eg, bowel obstruction, volvulus, tube feed intolerance). Esophagectomy and jejunostomy tube–related readmissions and nutritional markers were also assessed during the jejunostomy tube indwelling time.</div></div><div><h3>Results</h3><div>Of the 215 patients, 177 experienced 459 events documented during 372 healthcare encounters. Nonserious adverse events occurred within 4 to 6 weeks after surgery with the peak at 3 to 4 weeks. Serious adverse events (4, 0.9%) were rare and occurred mostly in the acute postoperative period. Thirty-five patients (16%) were readmitted during their jejunostomy tube indwelling time, of whom 14 (7%) were readmitted due to jejunostomy tube–related issues. Jejunostomy tube–related events were not predictors for readmission. Nutritional status stabilized within 30 days of surgery.</div></div><div><h3>Conclusions</h3><div>Serious adverse events after routine jejunostomy tube placement postesophagectomy are rare and occur mostly in the immediate postoperative period. Nonserious adverse events are more common and can be resource-intensive, providing an opportunity for improvement. Readmissions for jejunostomy tube complications are low. Nutritional status is appropriately maintained with supplemental jejunostomy tube feeding postesophagectomy. These findings suggest that routine jejunostomy tube placement at the time of esophagectomy can be a reasonable management strategy as part of a delayed feeding algorithm.</div></div>","PeriodicalId":74032,"journal":{"name":"JTCVS open","volume":"23 ","pages":"Pages 276-287"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143465188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tricuspid valve replacement with bioprostheses: Which type fits best?","authors":"Uberto Bortolotti MD","doi":"10.1016/j.xjon.2024.11.003","DOIUrl":"10.1016/j.xjon.2024.11.003","url":null,"abstract":"","PeriodicalId":74032,"journal":{"name":"JTCVS open","volume":"23 ","pages":"Page 109"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143464402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}